NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY
Comparative analysis of oral anticoagulants (vitamin K antagonists and new drugs, including dabigatran, rivaroxaban and apixaban) is presented from the standpoint of safety. The safety profile of the new oral anticoagulants is significantly better than vitamin K antagonists profile, but requires con...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2015-09-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/193 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849227979450744832 |
|---|---|
| author | D. A. Napalkov A. A. Sokolova |
| author_facet | D. A. Napalkov A. A. Sokolova |
| author_sort | D. A. Napalkov |
| collection | DOAJ |
| description | Comparative analysis of oral anticoagulants (vitamin K antagonists and new drugs, including dabigatran, rivaroxaban and apixaban) is presented from the standpoint of safety. The safety profile of the new oral anticoagulants is significantly better than vitamin K antagonists profile, but requires consideration of special clinical situations that predispose to an increased risk of bleeding. |
| format | Article |
| id | doaj-art-ef1ad42a0e174de288e3ca64e74cc1fa |
| institution | Kabale University |
| issn | 1819-6446 2225-3653 |
| language | English |
| publishDate | 2015-09-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj-art-ef1ad42a0e174de288e3ca64e74cc1fa2025-08-23T10:00:17ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532015-09-0110444444710.20996/1819-6446-2014-10-4-444-447193NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETYD. A. Napalkov0A. A. Sokolova1I.M. Sechenov First Moscow State Medical UniversityI.M. Sechenov First Moscow State Medical UniversityComparative analysis of oral anticoagulants (vitamin K antagonists and new drugs, including dabigatran, rivaroxaban and apixaban) is presented from the standpoint of safety. The safety profile of the new oral anticoagulants is significantly better than vitamin K antagonists profile, but requires consideration of special clinical situations that predispose to an increased risk of bleeding.https://www.rpcardio.online/jour/article/view/193anticoagulantsatrial fibrillationprevention of thromboembolismwarfarindabigatranrivaroxabanapixaban |
| spellingShingle | D. A. Napalkov A. A. Sokolova NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY Рациональная фармакотерапия в кардиологии anticoagulants atrial fibrillation prevention of thromboembolism warfarin dabigatran rivaroxaban apixaban |
| title | NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY |
| title_full | NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY |
| title_fullStr | NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY |
| title_full_unstemmed | NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY |
| title_short | NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY |
| title_sort | new oral anticoagulants focus on the safety |
| topic | anticoagulants atrial fibrillation prevention of thromboembolism warfarin dabigatran rivaroxaban apixaban |
| url | https://www.rpcardio.online/jour/article/view/193 |
| work_keys_str_mv | AT danapalkov neworalanticoagulantsfocusonthesafety AT aasokolova neworalanticoagulantsfocusonthesafety |